92-02-4

Usage

Uses

Used in Pharmaceutical Industry:
N-(3-Bis(2-hydroxyethylamino)phenyl)acetamide is used as an intermediate for the synthesis of various drugs and active pharmaceutical ingredients (APIs) due to its versatile chemical structure and potential therapeutic properties.
Used in Antiviral Applications:
N-(3-Bis(2-hydroxyethylamino)phenyl)acetamide is used as an antiviral agent, exhibiting potential activity against various viral infections. Its antiviral properties make it a promising candidate for the development of new antiviral drugs.
Used in Anticancer Applications:
N-(3-Bis(2-hydroxyethylamino)phenyl)acetamide is used as an anticancer agent, showing potential activity against different types of cancer. Its ability to target and inhibit cancer cells makes it a valuable compound in the search for novel cancer therapies.
Used in Anti-inflammatory Applications:
N-(3-Bis(2-hydroxyethylamino)phenyl)acetamide is used as an anti-inflammatory agent, demonstrating potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions. Its anti-inflammatory properties contribute to its potential use in the development of new treatments for various inflammatory diseases.
Used in Drug Discovery and Development:
N-(3-Bis(2-hydroxyethylamino)phenyl)acetamide is used as a building block for the creation of novel compounds and drug candidates. Its diverse applications and potential therapeutic properties make it a valuable asset in the field of drug discovery and development, contributing to the advancement of new and innovative treatments for various diseases and conditions.

InChI:InChI=1/C12H18N2O3/c1-10(17)13-11-3-2-4-12(9-11)14(5-7-15)6-8-16/h2-4,9,15-16H,5-8H2,1H3,(H,13,17)

Upstream product

• 102-28-3 m-acetamide aniline 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 27059-08-1 3-(N,N-di(acetyloxyethyl)amino)-N-phenylacetamide 
• 80751-19-5 N-{2-(4,6-Bis-dimethylamino-[1,3,5]triazin-2-ylazo)-5-[bis-(2-hydroxy-ethyl)-amino]-phenyl}-acetamide 
• 1268821-35-7 4'-(3-acetamidophenyl)spiro[indoline-1,1'-piperazin]-1-ium chloride 
• 13686-20-9 N,N-bis(2-chloroethyl)-3-acetamidoaniline 
• 22964-45-0 N,N-bis(2-(methylsulfonyloxy)ethyl)-3-acetamidoaniline 
• 149054-45-5 N-[5-{bis-(2-hydroxyethyl)-amino}-2-(4-cyano-3-methylisothiazol-5-ylazo)-phenyl]-acetamide 
• 14071-35-3 N-{5-(bis(2-hydroxyethyl)amino)-2-[(2-bromo-6-cyano-4-nitrophenyl)azo]phenyl}acetamide 
• 1357264-57-3 N-(5-(bis(2-hydroxyethyl)amino)-2-((2,6-dibromo-4-butylphenyl)diazenyl)phenyl)-acetamide 
• 71500-42-0 1-amino-3-[bis(2'-hydroxyethyl)amino]benzene 
• 1357264-92-6 N-(5-(bis(2-hydroxyethyl)amino)-2-((2,6-dicyano-4-nitrophenyl)diazenyl)phenyl)-acetamide 
• 1357264-93-7 2,2'-(3-acetamido-4-((2,6-dicyano-4-nitrophenyl)diazenyl)phenylazanediyl)bis(ethane-2,1-diyl)bis(2-methylacrylate) 
• 1357264-08-4 2-methacrylic acid 2-{[3-acetylamino-4-(4-cyano-3-methylisothiazol-5-ylazo)-phenyl]-[2-(2-methacryloyloxy)-ethyl]-amino}-ethyl ester 
• 1357264-25-5 3-chloropropionic acid 2-[{3-acetylamino-4-(4-cyano-3-methylisothiazol-5-ylazo)-phenyl}-{2-(3-chloropropionyloxy)-ethyl}-amino]-ethyl ester 
• 1357264-27-7 acrylic acid 2-[{3-acetylamino-4-(4-cyano-3-methylisothiazol-5-ylazo)-phenyl}-{2-acryloyloxyethyl}-amino]-ethyl ester 

Relevant academic research and scientific papers

Synthesis and structure-analgesic activity relationships of a novel series of monospirocyclopiperazinium salts (MSPZ)

A series of monospirocyclopiperazinium salts were designed and synthesized to search for a peripherally-acting analgesic drug with low side effects. Extensive SAR studies revealed that a suitable NR2R3 was critical for the analgesic activity, which might be beneficial to expose the cationic nitrogen to bind to the receptor, and possibly interact with the receptor via π-π interaction. Introduction of substituting group on the N4-phenyl ring could improve the activity, and the best position was the 4-position. Compound 14n showed more potent analgesic activity (63%, 20 μM/kg, sc) and holds promise for development as a mechanically new analgesic drug.